Vrijens, BernardDima, Alexandra L.Van Ganse, Ericvan Boven, Job F. M.Eakin, Michelle N.Foster, Juliet M.de Bruin, MarijnChisholm, AlisonPrice, David2016-09-012016-09-012016-09Vrijens, B, Dima, A L, Van Ganse, E, van Boven, J F M, Eakin, M N, Foster, J M, de Bruin, M, Chisholm, A & Price, D 2016, 'What We Mean When We Talk About Adherence In Respiratory Medicine', The Journal of Allergy and Clinical Immunology: In Practice, vol. 4, no. 5, pp. 802-812. https://doi.org/10.1016/j.jaip.2016.05.0192213-2198http://hdl.handle.net/2164/7432The Respiratory Effectiveness Group (REG; www.effectivenessevaluation.org) supported the Expert Adherence Panel Meeting at which many of the concepts presented in this paper were first discussed. REG also supported the manuscript submission costs. ALD, EvG, and MdB have received funding from the European Community's 7th Framework (FP7/2007-2013) under grant agreement no. 282593. Teva supported the meeting costs at which the concepts in this paper were discussed by the co-authors and the open access publication fee for this article. The authors had full editorial control over the ideas presented.11945026engmedication adherenceasthmachronic obstructive pulmonary disease (COPD)initiationimplementationpersistenceABC taxonomyR MedicineRJournal article10.1016/j.jaip.2016.05.01945